CS
RPRX icon

Credit Suisse’s Royalty Pharma RPRX Stock Holding History

Credit Suisse’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$30.2M Buy
994,993
+191,288
+24% +$5.64M 0.03% 522
2023
Q4 		$22.6M Buy
803,705
+134,654
+20% +$3.7M 0.02% 633
2023
Q3 		$18.2M Sell
669,051
-2,468
-0.4% -$73.3K 0.02% 663
2023
Q2 		$20.6M Buy
671,519
+170,988
+34% +$5.79M 0.02% 655
2023
Q1 		$18M Buy
500,531
+90,024
+22% +$3.34M 0.02% 708
2022
Q4 		$16.2M Sell
410,507
-3,891
-0.9% -$162K 0.02% 737
2022
Q3 		$16.6M Buy
414,398
+15,788
+4% +$674K 0.02% 724
2022
Q2 		$16.8M Buy
398,610
+28,629
+8% +$1.17M 0.02% 750
2022
Q1 		$14.4M Buy
369,981
+105,189
+40% +$4.13M 0.01% 888
2021
Q4 		$10.6M Buy
264,792
+109,480
+70% +$4.25M 0.01% 1470
2021
Q3 		$5.61M Buy
155,312
+4,428
+3% +$172K ﹤0.01% 1959
2021
Q2 		$6.18M Buy
150,884
+34,937
+30% +$1.49M ﹤0.01% 1913
2021
Q1 		$5.06M Buy
115,947
+39,568
+52% +$1.88M ﹤0.01% 2060
2020
Q4 		$3.82M Buy
+76,379
New +$3.24M ﹤0.01% 2316

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's RPRX Position: Q1 2024 in Review

Credit Suisse increased its Royalty Pharma (RPRX) stake by 24% in Q1 2024, buying an estimated $5.64M and bringing the position to 994,993 shares worth $30.2M. The position accounts for 0.03% of the portfolio, ranked #522.

Credit Suisse first reported a position in RPRX in Q4 2020 and has held it in 14 quarters since. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

  • Credit Suisse held 994,993 shares of Royalty Pharma worth $30.2M as of Q1 2024.
  • Credit Suisse bought 191,288 Royalty Pharma shares in Q1 2024, an estimated $5.64M.
  • Royalty Pharma made up 0.03% of Credit Suisse's portfolio in Q1 2024, its #522 holding.
  • Credit Suisse first reported a position in Royalty Pharma in Q4 2020 and has held it in 14 quarters since.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.